# Niraparib with postoperative radiotherapy in residual TNBC

Source: https://onco.cc/trials/nct03945721/  
OnCo record `nct03945721` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Niraparib is studied with radiation after breast surgery. The study is active but is not accepting new participants.

## Summary

Registry status active not recruiting, last updated 2026-06-17. Enrollment is 21 actual. Residual non-metastatic TNBC after definitive surgery, with planned postoperative radiation. The registry requires residual invasive disease after neoadjuvant chemotherapy, or at least 1 cm for surgery-first patients, performance status and organ-function gates, and discontinuation of cytotoxic, immune and biologic treatment before RT. This phase 1 safety strategy does not establish recurrence prevention or current access.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Registry id: NCT03945721
- Phase: 1
- Setting: Residual non-metastatic TNBC after definitive surgery, with planned postoperative radiation
- Sponsor: Massachusetts General Hospital
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT03945721: https://clinicaltrials.gov/study/NCT03945721

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Niraparib](https://onco.cc/drugs/niraparib/)

---
JSON: https://onco.cc/api/v1/entities/nct03945721.json